Skip to main content

Client News

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

21st October 2025

Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe

21st October 2025

ActiTrexx completes treatment of last patient with novel regulatory T cell therapy against Graft-versus-Host Disease

20th October 2025

Andera Partners co-leads €105 million Series A round for Adcytherix, its first investment from the BioDiscovery 7 fund

16th October 2025

TVM CAPITAL LIFE SCIENCE PORTFOLIO COMPANY SMART REPORTING TO ACQUIRE FLUENCY FOR IMAGING – UNITING TO CREATE JACOBIAN AND ACCELERATE AI-POWERED REPORTING

16th October 2025

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America

16th October 2025

Mainz Biomed to Attend 2025 Maxim Growth Summit 

15th October 2025

Andera Partners Reinvests in Tubulis’ €308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

15th October 2025

QUANTRO Therapeutics extends collaboration with Boehringer Ingelheim to address high unmet needs in cancer patients

14th October 2025

Together We Build: Rentschler Biopharma celebrates construction progress of new buffer media facility, largest single investment at Laupheim site

13th October 2025